Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
80.5M
-
Shares change
-
+1.17M
-
Total reported value, excl. options
-
$101M
-
Value change
-
+$1.89M
-
Put/Call ratio
-
0.38
-
Number of buys
-
64
-
Number of sells
-
-53
-
Price
-
$1.26
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q3 2025
159 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q3 2025.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.5M shares
of 114M outstanding shares and own 70.39% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (12.9M shares), BlackRock, Inc. (10.7M shares), VANGUARD GROUP INC (8.8M shares), Wilshire Advisors LLC (8.49M shares), JOHNSON & JOHNSON (3.38M shares), ACADIAN ASSET MANAGEMENT LLC (2.71M shares), GEODE CAPITAL MANAGEMENT, LLC (2.53M shares), Vestal Point Capital, LP (2.52M shares), STATE STREET CORP (2.42M shares), and DIMENSIONAL FUND ADVISORS LP (2.09M shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.